Tempest Therapeutics, Inc. Proceeds from Sale and Maturity of Marketable Securities
Tempest Therapeutics, Inc. (TPST) reported Proceeds from Sale and Maturity of Marketable Securities of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-29.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2021-03-29
- Tempest Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2020-12-31 was $0.00.
- Tempest Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2020-09-30 was $0.00.
- Tempest Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2020-06-30 was $0.00, a 100.00% decline year-over-year.
- Tempest Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- Tempest Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- Tempest Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2019 was $4.38M, a 75.96% increase from fiscal 2018.
- Tempest Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2018 was $2.49M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $0.00 derived: sum of 2 quarters · filed 2021-03-29 | $0.00 derived: sum of 3 quarters · filed 2021-03-29 | $0.00 10-K · filed 2021-03-29 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $0.00 10-Q · filed 2020-11-09 | $0.00 derived: sum of 4 quarters · filed 2021-03-29 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $0.00 10-Q · filed 2020-08-10 | $0.00 derived: sum of 3 quarters · filed 2021-03-29 | $0.00 derived: sum of 4 quarters · filed 2021-03-29 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-08 | $0.00 derived: sum of 2 quarters · filed 2021-03-29 | $0.00 derived: sum of 3 quarters · filed 2021-03-29 | $1.40M derived: sum of 4 quarters · filed 2021-03-29 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $0.00 derived: sum of 2 quarters · filed 2021-03-29 | $1.40M derived: sum of 3 quarters · filed 2021-03-29 | $4.38M 10-K · filed 2021-03-29 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $1.40M derived: sum of 2 quarters · filed 2020-11-09 | $4.38M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $4.38M 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $2.99M 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | $2.49M 10-K · filed 2020-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |